経皮ドラッグデリバリーシステム市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

経皮ドラッグデリバリーシステム市場は、2023年に69億8,000万米ドルと評価され、2024年には73億2,000万米ドルに達すると予測され、CAGR 5.06%で成長し、2030年には98億7,000万米ドルに達すると予測されています。

経皮ドラッグデリバリーシステム（TDDS）は、経口や注射に代わる非侵襲的な方法として、皮膚から薬剤を投与するものです。その必要性は、一貫した治療効果、患者のコンプライアンス向上、従来の送達メカニズムにありがちな副作用の最小化に対する需要の高まりから生じています。このシステムは、疼痛管理、ホルモン治療、ニコチン禁煙など、複数の治療領域に適用可能であり、皮膚科から循環器系まで幅広い最終用途に汎用されています。市場成長は、薬剤製剤技術の進歩、慢性疾患の増加、痛みを伴わない薬剤投与に対する患者の嗜好、革新的なドラッグデリバリーシステムへのシフトによって大きく左右されます。ナノテクノロジーやバイオマテリアルを活用することで、ペプチドやワクチンなどの複雑な治療薬を送達できる多機能TDDS技術の開発には機会が豊富にあります。企業は、研究協力に投資し、製品ポートフォリオを拡大することで、こうした可能性を活用することができます。しかし、市場は高い開発コスト、厳しい規制要件、皮膚に関連する刺激性の問題などの課題に直面しており、これが普及の妨げになる可能性があります。効果的な浸透促進剤の配合は依然として重要な研究分野であり、副作用なしに薬物浸透を最適化できる革新的な物質や技術に焦点が当てられています。消費動向が個別化医療に傾く中、イノベーションの重要な領域は、データ分析と予測モデリングにおけるAIの活用により、個々の患者のニーズに沿った、よりテーラーメイドの経皮ソリューションを生み出すことにあります。市場はダイナミックで、製薬大手と新興新興企業がバランスよくイノベーションをリードしています。長期的な成長を目指す企業は、業界を超えたパートナーシップとTDDSの有効性と安全性プロファイルの継続的な改善を優先し、自社の製品がテクノロジーと患者ケアの動向の最前線にあり続けるようにすべきです。

市場力学：急速に進化する経皮ドラッグデリバリーシステム市場の主要市場インサイトを公開

経皮ドラッグデリバリーシステム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と効果的なドラッグデリバリーの必要性
  • 第三世代の急速な普及
• 市場抑制要因
  • パッチ使用時の刺激や皮膚過敏症に関する懸念
• 市場機会
  • 経皮ドラッグデリバリーシステムの継続的研究開発
  • 製薬企業とTDDSベンダーの無機的成長戦略
• 市場の課題
  • 経皮吸収型テープ製剤による薬物障害のリスクと製品回収の可能性

ポーターのファイブフォース：経皮ドラッグデリバリーシステム市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：経皮ドラッグデリバリーシステム市場における外部からの影響の把握

外部マクロ環境要因は、経皮ドラッグデリバリーシステム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析経皮ドラッグデリバリーシステム市場における競合情勢の把握

経皮ドラッグデリバリーシステム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス経皮ドラッグデリバリーシステム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、経皮ドラッグデリバリーシステム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と効果的なドラッグデリバリーの必要性
    • 第3世代の採用が急増経皮ドラッグデリバリーシステム
  • 抑制要因
    • パッチの使用による刺激や皮膚の敏感さに関する懸念
  • 機会
    • 経皮ドラッグデリバリーシステムにおける継続的な研究開発
    • 製薬企業とTDDSベンダー間の無機的成長戦略
  • 課題
    • 経皮吸収システムと製品リコールによる薬剤の失敗の可能性のあるリスク
• 市場セグメンテーション分析
  • タイプ：経皮パッチの規制および政府による承認が進行中
  • 応用：心血管疾患の管理のための低侵襲性ドラッグデリバリーシステムの必要性
  • エンドユーザー：薬剤の自己投与が好まれるため、在宅ケアの環境で実施できるドラッグデリバリーシステムの需要が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 経皮ドラッグデリバリーシステム市場：タイプ別

• 経皮パッチ
  • 薬剤接着パッチ
  • マトリックスパッチ
  • マイクロニードルパッチ
  • リザーバー膜パッチ
• 経皮吸収型半固形剤
  • ジェル
  • 軟膏
  • スプレー

第7章 経皮ドラッグデリバリーシステム市場：用途別

• 心血管疾患
• 中枢神経系疾患
• ホルモンの応用
• 疼痛管理
• 経皮エストロゲン療法

第8章 経皮ドラッグデリバリーシステム市場：エンドユーザー別

• ホームケア設定
• 病院・クリニック

第9章 南北アメリカの経皮ドラッグデリバリーシステム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の経皮ドラッグデリバリーシステム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの経皮ドラッグデリバリーシステム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 呂業薬のリバスチグミン週2回経皮パッチが中国でアルツハイマー病治療として承認
  • サティオ、在宅経皮ドラッグデリバリーデバイスの開発で350万米ドルの契約を獲得
  • LTS、ソレルウェアラブル注射デバイス事業の買収により高分子ドラッグデリバリーへの参入を完了
  • DifGen PharmaceuticalsがAvevaドラッグデリバリーServices Inc.を買収
  • ザイダス・ライフサイエンス社、エストラジオール経皮吸収システムの販売について米国FDAから最終承認を取得
  • キンデバがメリディアンと合併し、医薬品と医療機器の組み合わせに特化した世界CDMOを設立
  • LTSローマンが無針出産専門企業への投資を主導
  • ラブファーマ、経皮オピオイド使用障害治療薬プレーヤーの買収に動く
  • コリウム、アルツハイマー型認知症患者向けにADLARITY（ドネペジル経皮吸収システム）を発売
  • Lowensteinは、Pharma Tech LTS Lohmann Therapy Systems, Corp.のTapemark Inc.買収を代理します。

企業一覧

• Novartis International AG
• Viatris Inc.
• 3M Company
• Biotts Inc.
• Nitto Denko Corporation
• Medherant Limited
• Lead Chemical Co., Ltd.
• Zynerba Pharmaceuticals, Inc.
• Purdue Pharma L.P.
• UCB S.A.
• Johnson & Johnson Services, Inc.
• Sorrento Therapeutics, Inc.
• Sparsha Pharma International Pvt. Ltd.
• IntelGenx Corp.
• Transdermal Therapeutics, Inc.
• Toa Eiyo Ltd.
• Gensco Pharma
• Bayer AG
• Luye Life Sciences Group
• Nutriband Inc.
• Zhongshan Senwell Bio Technology Co., Ltd.
• Starton Therapeutics
• Lavipharm S.A.
• Kindeva Drug Delivery L.P.
• Hisamitsu Pharmaceutical Co., Inc.
• IBSA Farmaceutici Italia Srl
• AdhexPharma, SAS
• Toyo Ink SC Holdings Co., Ltd.
• DuPont de Nemours, Inc.
• Boehringer Ingelheim International GmbH

LIST OF FIGURES

• FIGURE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
• FIGURE 2. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET DYNAMICS
• TABLE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY RESERVOIR MEMBRANE PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HORMONAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL ESTROGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 46. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 73. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 74. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 78. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 79. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 164. ITALY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 165. ITALY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 184. POLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 185. POLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 189. QATAR TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 190. QATAR TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023

The Transdermal Drug Delivery System Market was valued at USD 6.98 billion in 2023, expected to reach USD 7.32 billion in 2024, and is projected to grow at a CAGR of 5.06%, to USD 9.87 billion by 2030.

The transdermal drug delivery system (TDDS) involves administering medication through the skin, offering a non-invasive alternative to oral or injectable methods. Its necessity arises from the growing demand for consistent therapeutic effects, improved patient compliance, and minimized side effects typically associated with traditional delivery mechanisms. This system is applicable across several therapeutic areas, including pain management, hormonal treatment, and nicotine cessation, making it versatile for a broad end-use scope, ranging from dermatology to cardiovascular health. Market growth is significantly influenced by advancements in drug formulation technologies, increased prevalence of chronic diseases, patient preference for painless drug administration, and a shifting focus towards innovative drug delivery systems. Opportunities abound in the development of multifunctional TDDS technology capable of delivering complex therapeutics, such as peptides and vaccines, by leveraging nanotechnology and biomaterials. Companies can benefit from investing in research collaborations and expanding their product portfolios to tap into these potentials. However, the market faces challenges such as high development costs, stringent regulatory requirements, and skin-related irritation issues, which could hamper widespread adoption. The inclusion of effective penetration enhancers remains a critical research area, focusing on innovative substances and technologies that can optimize drug permeation without adverse effects. As consumption trends tilt towards personalized medicine, a significant area of innovation lies in creating more tailored transdermal solutions that align with individual patient needs, utilizing data analytics and AI in predictive modeling. The market is dynamic, with a balanced representation of pharmaceutical giants and emerging startups leading innovation. Firms aiming for long-term growth should prioritize cross-industry partnerships and continual improvements in TDDS efficacy and safety profiles, ensuring that their offerings remain at the forefront of technology and patient care trends.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transdermal Drug Delivery System Market

The Transdermal Drug Delivery System Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and the need for effective drug delivery
  • Surging adoption of third-generation transdermal drug delivery system
• Market Restraints
  • Concerns associated with irritation or skin sensitivity over patch usage
• Market Opportunities
  • Ongoing research & development in transdermal drug delivery system
  • Inorganic growth strategies between pharmaceutical companies and TDDS vendors
• Market Challenges
  • Probable risk of drug failure through transdermal systems and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Transdermal Drug Delivery System Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transdermal Drug Delivery System Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Transdermal Drug Delivery System Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transdermal Drug Delivery System Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Transdermal Drug Delivery System Market

A detailed market share analysis in the Transdermal Drug Delivery System Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transdermal Drug Delivery System Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transdermal Drug Delivery System Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include Novartis International AG, Viatris Inc., 3M Company, Biotts Inc., Nitto Denko Corporation, Medherant Limited, Lead Chemical Co., Ltd., Zynerba Pharmaceuticals, Inc., Purdue Pharma L.P., UCB S.A., Johnson & Johnson Services, Inc., Sorrento Therapeutics, Inc., Sparsha Pharma International Pvt. Ltd., IntelGenx Corp., Transdermal Therapeutics, Inc., Toa Eiyo Ltd., Gensco Pharma, Bayer AG, Luye Life Sciences Group, Nutriband Inc., Zhongshan Senwell Bio Technology Co., Ltd., Starton Therapeutics, Lavipharm S.A., Kindeva Drug Delivery L.P., Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, AdhexPharma, SAS, Toyo Ink SC Holdings Co., Ltd., DuPont de Nemours, Inc., and Boehringer Ingelheim International GmbH.

Market Segmentation & Coverage

This research report categorizes the Transdermal Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Transdermal Patches and Transdermal Semisolids. The Transdermal Patches is further studied across Drug-In-Adhesive Patches, Matrix Patches, Microneedle Patches, and Reservoir Membrane Patches. The Transdermal Semisolids is further studied across Gels, Ointments, and Sprays.
• Based on Application, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications, Pain Management, and Transdermal Estrogen Therapy.
• Based on End User, market is studied across Home Care Settings and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and the need for effective drug delivery
    • 5.1.1.2. Surging adoption of third-generation transdermal drug delivery system
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research & development in transdermal drug delivery system
    • 5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
  • 5.1.4. Challenges
    • 5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Ongoing regulatory and government approvals for transdermal patches
  • 5.2.2. Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases
  • 5.2.3. End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Transdermal Drug Delivery System Market, by Type

• 6.1. Introduction
• 6.2. Transdermal Patches
  • 6.2.1. Drug-In-Adhesive Patches
  • 6.2.2. Matrix Patches
  • 6.2.3. Microneedle Patches
  • 6.2.4. Reservoir Membrane Patches
• 6.3. Transdermal Semisolids
  • 6.3.1. Gels
  • 6.3.2. Ointments
  • 6.3.3. Sprays

7. Transdermal Drug Delivery System Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular Diseases
• 7.3. Central Nervous System Disorders
• 7.4. Hormonal Applications
• 7.5. Pain Management
• 7.6. Transdermal Estrogen Therapy

8. Transdermal Drug Delivery System Market, by End User

• 8.1. Introduction
• 8.2. Home Care Settings
• 8.3. Hospitals & Clinics

9. Americas Transdermal Drug Delivery System Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Transdermal Drug Delivery System Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Transdermal Drug Delivery System Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
  • 12.3.2. Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device
  • 12.3.3. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
  • 12.3.4. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
  • 12.3.5. Zydus Lifesciences gets Final Approval from the U.S. FDA to Market Estradiol Transdermal System
  • 12.3.6. Kindeva Merges with Meridian to Create Global CDMO Specializing in Drug-Device Combinations
  • 12.3.7. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
  • 12.3.8. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
  • 12.3.9. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer's Dementia
  • 12.3.10. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.

Companies Mentioned

• 1. Novartis International AG
• 2. Viatris Inc.
• 3. 3M Company
• 4. Biotts Inc.
• 5. Nitto Denko Corporation
• 6. Medherant Limited
• 7. Lead Chemical Co., Ltd.
• 8. Zynerba Pharmaceuticals, Inc.
• 9. Purdue Pharma L.P.
• 10. UCB S.A.
• 11. Johnson & Johnson Services, Inc.
• 12. Sorrento Therapeutics, Inc.
• 13. Sparsha Pharma International Pvt. Ltd.
• 14. IntelGenx Corp.
• 15. Transdermal Therapeutics, Inc.
• 16. Toa Eiyo Ltd.
• 17. Gensco Pharma
• 18. Bayer AG
• 19. Luye Life Sciences Group
• 20. Nutriband Inc.
• 21. Zhongshan Senwell Bio Technology Co., Ltd.
• 22. Starton Therapeutics
• 23. Lavipharm S.A.
• 24. Kindeva Drug Delivery L.P.
• 25. Hisamitsu Pharmaceutical Co., Inc.
• 26. IBSA Farmaceutici Italia Srl
• 27. AdhexPharma, SAS
• 28. Toyo Ink SC Holdings Co., Ltd.
• 29. DuPont de Nemours, Inc.
• 30. Boehringer Ingelheim International GmbH